The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in first-line metastatic pancreatic cancer (MPC): Updated results.
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Abbvie; Amgen; Gilead Sciences; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Cornerstone Pharmaceuticals; Gilead Sciences; Halozyme
Research Funding - Aduro Biotech; Celgene; FibroGen; Immunomedics; OncoMed
 
Bruce Shih-Li Lin
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Aduro Biotech (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Sillajen (Inst)
 
Margaret T. Mandelson
No Relationships to Disclose